Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8809 - 8816 of 12085 results
New York City Commission on Human Rights Releases Enforcement Guidance on Gender Identity and Expression Discrimination (NYC Finale Part 1)
December 29, 2015| Blog| Viewpoint
Corporate Counsel: What Employees Can Legally Say on Facebook – And Get Away With
December 29, 2015| Blog| Viewpoint
Laboratories - 2015 Year in Review [VIDEO]
December 29, 2015| Blog| Viewpoint
Review of 2015 Federal Circuit Decisions Addressing IPR Claim Construction and Procedural Issues
December 29, 2015| Blog| Viewpoint
A Return to Evanston: FTC Revisits Old Ground in Yet Another Hospital Merger Challenge
December 23, 2015| Blog| Viewpoint
Congress Erects Hurdle for CPSC’s Recreational Off-Highway Vehicle Rulemaking in 2016 Omnibus Bill
December 22, 2015| Blog| Viewpoint
Federal Circuit Rules Federal Trademark Statute Ban on DIsparaging Marks to Be Unconstitutional
December 22, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|